{"id":"NCT01299272","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Prevention of Re-emergence of Depression Symptoms","officialTitle":"LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2011-02-18","resultsPosted":"2018-04-17","lastUpdate":"2018-04-17"},"enrollment":1249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"LY2216684","otherNames":["Edivoxetine"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SSRI","otherNames":["Selective Serotonin Reuptake Inhibitor"]}],"arms":[{"label":"LY2216684 + SSRI","type":"EXPERIMENTAL"},{"label":"Placebo + SSRI","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to assess the maintenance of efficacy of LY2216684 compared with placebo as adjunctive therapy to selective serotonin reuptake inhibitors (SSRIs) as measured by the time-to-symptom reemergence among participants with major depressive disorder (MDD) who met randomization criteria with adjunctive LY2216684 during the stabilization period.\n\nThis trial consists of two distinct periods: an open-label treatment period, which consists of two parts, 8 weeks acute open-label with movement to 12 weeks open-label stabilization if participants are in remission at end of 8 weeks (open-label for 20 weeks total) followed by a randomized, double-blind, placebo-controlled period for 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period)","timeFrame":"Randomization up to 44 weeks","effectByArm":[{"arm":"LY2216684 + SSRI","deltaMin":10.43,"sd":null},{"arm":"Placebo + SSRI","deltaMin":8.24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.485"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":77,"countries":["United States","Argentina","Belgium","Croatia","France","Germany","Greece","Italy","Mexico","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["25894953"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":1244},"commonTop":["Hyperhidrosis","Headache","Nausea","Constipation","Dizziness"]}}